Printer Friendly

ALPHA-BETA TECHNOLOGY, INC. REPORTS 1993 THIRD QUARTER RESULTS

 WORCESTER, Mass., Oct. 29 /PRNewswire/ -- Alpha-Beta Technology, Inc. (NASDAQ: ABTI) reported today financial results for the third quarter and nine months ended September 30, 1993. In the third quarter, there was a net loss of $3,398,758 or $0.34 per share on revenues of $214,080 and expenses of $3,612,838. During the third quarter of last year, the company reported revenues of $98,488, expenses of $1,665,551, and a resulting net loss of $1,567,063, or $.21 per share.
 For the nine month period ending September 30, 1993, revenues totaled $570,534, expenses were $9,884,652, and there was a net loss of $9,314,118, or $0.99 per share. In the comparable period of 1992, there was a net loss of $4,288,901, or $.58 per share, on revenues of $374,818 and expenses of $4,663,719.
 "During the quarter, the clinical development program for Betafectin(TM), our receptor targeted carbohydrate, continued to advance rapidly through Phase II trials for the prevention and treatment of infections following major surgery," said Spiros Jamas, Sc.D., President and CEO of Alpha-Beta. "We completed a second, multi-center Phase II trial in sixty patients undergoing major chest and abdominal surgery. The preliminary results of this trial confirmed the results of our first thirty patient, placebo-controlled Phase II trial which were presented by the clinical investigator at the American College of Surgeons annual Clinical Congress in October 1993. The investigator reported that, in the first study, Betafectin produced a significant reduction in infectious complications, and that Betafectin-treated patients spent five fewer days in the hospital and three fewer days in intensive care compared to the placebo group."
 In addition, Alpha-Beta is proceeding with the development of Cholazol(TM) (formerly Cholestran(TM)), for the treatment of elevated cholesterol levels.
 Alpha-Beta Technology, Inc. is developing patentable carbohydrate- based products for the health care industry through the application of carbohydrate engineering. The Company's major products in development include Betafectin for the treatment and prevention of infections; Cholazol for the treatment and prevention of cardiovascular disease; and Fibercel(TM), a fat substitute. Alpha-Beta's headquarters, laboratory and pilot production facilities are located in Worcester, Mass.
 ALPHA-BETA TECHNOLOGY, INC. AND SUBSIDIARY
 Condensed Consolidated Statement of Operations
 (unaudited)
 Three Months Ended Nine Months Ended
 Sept. 30, Sept. 30,
 1993 1992 1993 1992
 Revenues:
 Product sales $4,265 $2,985 $19,110 $17,203
 Interest income 209,815 95,503 548,598 354,102
 Other income 0 0 2,826 3,513
 Total revenues 214,080 98,488 570,534 374,818
 Expenses:
 Research and
 development 2,649,546 1,080,859 7,037,355 2,894,704
 General and
 administrative 937,901 568,017 2,765,971 1,706,914
 Interest expense 25,391 16,675 81,326 62,101
 Total expenses 3,612,838 1,665,551 9,884,652 4,663,719
 Net loss $(3,398,758) $(1,567,063)(9,314,118)(4,288,901)
 Net loss per share (34 cents) (21 cents) (99 cents)(58 cents)
 Shares used in
 calculation of
 net loss per
 share 10,103,834 7,515,077 9,441,671 7,429,369
 CONDENSED CONSOLIDATED BALANCE SHEETS
 Sept. 30, Dec. 31,
 1993 1992
 (Unaudited)
 Cash, cash
 equivalents,
 & short-term
 investments $23,526,309 $23,810,781
 Other current assets 626,131 371,559
 Total current assets 24,152,440 24,182,340
 Long-term investments 3,682,400 997,648
 Property and equipment,
 net 14,258,148 3,204,947
 Other assets, net 23,085,435 515,852
 Total assets $65,178,423 $28,900,787
 Current liabilities $1,464,107 $2,207,459
 Non-current liabilities 27,066,581 543,042
 Stockholders' equity 36,647,735 26,150,286
 Total liabilities &
 stockholders' equity $65,178,423 $28,900,787
 -0- 10/29/93
 /CONTACT: Braden M. Bohrmann, chief financial officer of Alpha-Beta Technology, 508-798-6900; or Robert Gottlieb, senior vice president of Feinstein Partners, 617-577-8110, for Alpha-Beta Technology/
 (ABTI)


CO: Alpha-Beta Technology, Inc. ST: Massachusetts IN: MTC SU: ERN

DD -- NE017 -- 8758 10/29/93 18:11 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 29, 1993
Words:683
Previous Article:BIRD CORPORATION THIRD QUARTER LOSS RESULTS FROM ENVIRONMENTAL GROUP OPERATIONS AND RESTRUCTURING
Next Article:PALMER TUBE REPORTS LOWER EARNINGS ON INCREASED REVENUES FOR FIRST QUARTER
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters